Sindusfarma Annual Activity Report 2024
Foreword
Cleiton de Castro Marques
President
Board of Directors 2025 – 2027
New headquarters. New scenario.
New perspectives. Broader horizons.
Sindusfarma begins a new cycle of expansion of its activities and services provided to associated companies, preserving and deepening the significant achievements accumulated during its long and successful trajectory.
The Board of Directors that has just taken over under my leadership is already actively engaged in this task.
We shall invest more resources and renewed vigor in defending the strategic topics of the pharmaceutical industry and its production chain.
We shall increase the number of studies that refine the arguments and foundations of our main claims.
We shall fight for the readjustment of the reference values of the Farmácia Popular Program and dialogue with the government to strengthen this winning state policy.
We shall address sensitive issues such as the misuse of compounding pharmacies.
The agenda is extensive. But we are prepared to lead it with strength and determination.
Let’s get to work!
Sindusfarma Annual Activity Report
Presentation
Nelson Mussolini
Executive President
A historical representative of all pharmaceutical industries established in the country, regardless of the origin of the capital – for 92 years – Sindusfarma has always been a great entity. But it lacked a landmark, an objective sign of its size.
Not anymore. The new headquarters building that Sindusfarma has just inaugurated embodies what the entity has always been: the reference point for the pharmaceutical industry operating in Brazil.
In record time (just one year) the new headquarters was built and delivered, fulfilling the mission determined by the Board of Directors.
A huge challenge, which was achieved thanks to the effort and dedication of Sindusfarma’s professionals and its partners.
In parallel with the new headquarters project Sindusfarma mobilized around Tax Reform, the review of the drug pricing model, the new Clinical Research law and a multitude of other issues, in addition to acting in various forums such as the National Health Council, National Health Surveillance Agency (Anvisa), Ministry of Health etc.
2024 was another year of intense activity in which Sindusfarma vigorously fulfilled its vocation of defending legitimate sectoral interests.
An intense action made possible by the Board of Directors which gave us the freedom and resources necessary to carry out the work presented in this Annual Activity Report.
